



Rebion (Boston, MA) is an early-revenue-stage company commercializing a disruptive platform technology called Neural Performance Scanning (NPS). NPS detects and monitors life-altering maladies and injuries of the brain, including our initial targets of lazy eye (amblyopia) and concussion / traumatic brain injury (TBI). Portable NPS devices provide faster and more accurate triage, making early detection, intervention, and treatment more impactful than ever before.

Rebion's first commercial product is Blinq®, a transformative device that in 3-seconds measures retinal fixation to detect lazy eye, the leading cause of pediatric blindness. Blinq is cleared by FDA and has a CPT code for insurance payments.

Rebion's follow-on product uses the same NPS platform for detection and monitoring of TBI, including concussions. Ongoing trials for FDA clearance will conclude in 2025, with additional studies being funded by the NIH.

## Technology

Virtually every disease and injury of the brain manifests in the brain's visual cortex. Thus, the eyes provide a "Window to the Brain". NPS measures brain/eye signaling that is otherwise unobtainable. By measuring retinal fixation, Rebion can identify and monitor a host of brain impairments including lazy eye, concussion/TBI, PTSD, chemical impairment, and other neurodegenerative disorders, including Alzheimer's Disease. Point-of-care NPS devices increase the quality of outcomes while lowering the cost of care. Varied NPS applications involve minimal design changes allowing for a myriad of business models for each addressable market, including point-of-care yes/no detection, annuity-based patient monitoring, digital home medicine, and AI assisted cloud-based metadata for research & drug/therapy development.

## Milestones

- FDA clearance (Blinq for amblyopia)
- Commercially launched with Blinq sales (2020)
- Contract manufacturing partnership with Canon (2021)
- TBI clinical validation published (2023)
- CPT reimbursement code specific to NPS
- NIH & industry-funded studies in Alzheimer's and PTSD (2024)

## Intellectual Property

Rebion's patent portfolio includes 7 issued US patents, 23 issued international patents, and 51 total IP assets.

## Blinq Market Opportunity

The US Blinq market is \$6370MM, with approximately 60,000 sales points. Lazy eye is the leading cause of preventable blindness worldwide. When identified early, treatment is 95% curative by low-cost eye-patches and glasses. Approximately 50% of all cases are currently missed, and failure to detect leads to permanent vision impairment.

## Traumatic Brain Injury (TBI) Market Opportunity

TBI screening is a \$3.5Bn US segment within the \$400Bn worldwide market. TBI is the leading cause of disability and death for individuals under the age of 35. By rapidly assessing brain function, Rebion's Traq™ device can provide a functional assessment at each touch point along the TBI patient journey from injury to recovery (or lack of recovery).

## Competition

Rebion is competing against outdated and ineffective technologies. Peer-reviewed studies show the unprecedented sensitivity and specificity of NPS versus the competition. Rebion's Blinq device is the only FDA-cleared device for the detection of amblyopia and strabismus.

## US Sales Strategy

Rebion has a direct-sales team and is exploring collaboration opportunities for global distribution.

## Global Opportunities

International Blinq expansion is targeted for 2025. Follow-on devices for other brain impairments will be judiciously assessed and deployed per regulatory clearances, sales networks, and strategic partnerships. Trials for Alzheimer's Disease and PTSD have been initiated with NIH & industry funding.

## Risks

Given FDA's clearance of Blinq, remaining risks include: supply chain efficiencies, sales/distribution cycles, and CPT code fluctuations. Additional human data must be collected for FDA-clearance of TBI and follow-on products.

## Funding

Rebion has raised \$17.0+MM, including \$4.0MM from NIH SBIR awards. Rebion is currently seeking \$5.0MM in Series B financing to accelerate TBI clinical trials, expand the sales organization, and position the company for a robust exit.

## Management Team

[Jeff Craig](mailto:jcraig@rebion.net): CEO & Managing Director (jcraig@rebion.net)

Seasoned bio-scientist and executive with multiple healthcare exits

[Justin Shaka](mailto:jgshaka@rebion.net): COO, Rebion Co-Founder (jgshaka@rebion.net)

Formerly at Boston Children's Hospital (BCH)

[Jeff Mortensen](#): EVP Sales

Formerly VP Business Development – Spot at Welch Allyn

[David G. Hunter, MD, PhD](#): Chairman of the Board

NPS co-inventor; Chief of Ophthalmology at Boston Children's; Vice-Chair of Ophthalmology at Harvard

